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Abstract
A prospective study was conducted during an 8-month period, from August 2006 to April 2007, to describe the epidemiology of Staphylo-
coccus aureus-associated infections. In addition, the molecular characteristics, antimicrobial susceptibilities and antibiotic resistance deter-
minants were identiﬁed in S. aureus isolates from hospitals and the community in Vladivostok, Russia. Among the 63 S. aureus isolates
eligible for this study, methicillin resistance was observed in 48% (n = 30). Hospital-acquired strains accounted for 93% (28/30) of all
methicillin-resistant S. aureus (MRSA) isolates. The major MRSA clone (sequence type (ST) 239, staphylococcal cassette chromosome mec
(SCCmec) type III, Panton–Valentine leukocidin (PVL)-negative, with two related staphylococcal protein A gene (spa) types (types 3 and
351)) represented 90% of all of the MRSA isolates. This clone was multidrug-resistant, and 41% of isolates showed resistance to rifampi-
cin. Community-acquired MRSA isolates (n = 2) were categorized as ST30, SCCmecIV, spa type 19, and PVL-positive, and as ST8,
SCCmecIV, of a novel spa type 826, and PVL-negative. Eight different STs were detected among methicillin-susceptible S. aureus (MSSA)
isolates, of which 55% were PVL-positive. One MSSA clone, which was categorized as ST121, spa type 273, and PVL-positive, caused fatal
community-acquired pneumonia infections. The strains predominantly isolated in hospitals in Russia belonged to the multidrug-resistant
Brazilian/Hungarian ST239 MRSA clone; however, this clone has new antibiotic susceptibilities. Additionally, the emergence of PVL-
positive MSSA strains with enhanced virulence was observed, warranting continued surveillance.
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Introduction
Staphylococcus aureus is of special concern because of its abil-
ity to cause a number of life-threatening conditions and its
widening resistance to currently available antimicrobial drugs
[1]. Methicillin-resistant S. aureus (MRSA), which harbours
the staphylococcal cassette chromosome mec (SCCmec), has
become a leading cause of hospital-acquired infections world-
wide, accounting for >60% of S. aureus isolates in US hospi-
tals [2]. Molecular epidemiological studies have shown the
spread of several MRSA clones internationally, in the hospital
setting. These epidemic hospital-acquired MRSA (HA-MRSA)
clones have been identiﬁed as the Archaic/Iberian (sequence
type (ST) 247, SCCmecI), Brazilian/Hungarian (ST239,
SCCmecIII), Berlin (ST45, SCCmecIV), New York/Japan (ST5,
SCCmecII), paediatric (ST5, SCCmecIV), EMRSA-15 (ST22,
SCCmecIV) and EMRSA-16 (ST36, SCCmecII) clones [3].
Since the mid-1990s, MRSA infection in healthy individuals
who do not have any of the known risk factors for MRSA
has increased. These community-acquired MRSA (CA-MRSA)
strains have a different genetic background from the
HA-MRSA strains, belong mainly to (ST1 (USA400; SCCme-
cIV), ST8 (USA300; SCCmecIV), ST30 (SCCmecIV), ST59
(USA1000; SCCmecIV), and ST80 (SCCmecIV), and are often
associated with the production of Panton–Valentine leuko-
cidin (PVL) [4]. PVL has been implicated in the pathogenesis
of severe infections caused by CA-MRSA, especially pneu-
monia [5].
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Methicillin-sensitive S. aureus (MSSA) isolates show greater
genetic diversity than MRSA isolates, and they provide a pool
of organisms for the emergence of new MRSA clones [6].
Hence, knowledge of the molecular characteristics of MSSA
is essential for controlling the potential emergence of new
epidemic MRSA clones.
Data on the antimicrobial resistance of S. aureus in Russia
have been reported [7], but the data on clonality, virulence
gene proﬁles and genetic determinants of antibiotic
resistance remain incomplete. The aims of this study were to
analyze the genetic characteristics of both community-
acquired and hospital-acquired MRSA and MSSA strains
isolated in Vladivostok, Russia, and to evaluate the antimicro-
bial susceptibilities of the isolates and the presence of
antibiotic resistance genes.
Materials and Methods
Bacterial strains
S. aureus isolates were collected from paediatric and adult
inpatients and outpatients using a systematic random sam-
pling method at four hospital laboratories in Vladivostok (the
largest city in the Primorsky region of Russia), from August
2006 to April 2007. The laboratories served the four Vlad-
ivostok city hospitals, which housed a combined total of
2124 beds and had more than 5000 outpatient visits per
year. Each of the laboratories was asked to provide a maxi-
mum of two S. aureus isolates per week, excluding samples
that were taken for ‘screening’ purposes. Patient data on
demographics, reason for admission, history of prior hospi-
talization, outcome, site of S. aureus infection, and site of
sample collection, and information on healthcare risk factors
for MRSA infection, were collected using a standard case
report form. HA-MRSA and CA-MRSA infections were
deﬁned as described previously [8]. This study was approved
by the Ethics Committee of the Vladivostok City Hospital.
S. aureus isolates were identiﬁed in accordance with ofﬁ-
cial Russian guidelines, using Gram staining, analysis of cata-
lase production, a tube coagulase test in 5% rabbit plasma,
and a lecithinase test performed on mannitol–salt agar. After
conﬁrmation of the identity of the strains at the Division of
Bacteriology, Niigata University, Japan, using standard identiﬁ-
cation procedures [9], and exclusion of duplicate isolates col-
lected from the same patient, 63 (of 170) S. aureus isolates
were eligible for study. Data on the basic demographics of
the patients and the clinical origin of S. aureus infection are
shown in Table 1.
Positive controls for PCR assays were kindly provided by
T. Yamamoto (Division of Bacteriology, Niigata University,
Japan). S. aureus ATCC 29213 was used as a quality control
strain in the MIC experiments.
Genotyping
Coagulase typing was performed using a coagulase typing kit
(Denka Seiken Co. Ltd, Tokyo, Japan), according to the man-
ufacturer’s instructions. Pulsed-ﬁeld gel electrophoresis
(PFGE) was performed using a CHEF DR III apparatus (Nip-
pon, Bio-Rad Laboratories) after SmaI digestion (Takara Bio
Inc., Japan) to characterize all S. aureus isolates, as described
previously [10]. Multiplex PCR-based protocols for allotyping
the accessory gene regulator (agr) and SCCmecI–IV and for
SCCmecIV subtyping (IVa, IVb, IVc, and IVd) were performed
as previously described, using reference strains [11–13].
Staphylococcal protein A gene (spa) typing was performed
using the eGenomics software package (http://tools.egenomics.
com/) [14]. Multilocus sequence typing of all 30 MRSA isolates
and 19 selected MSSA isolates was performed as described
elsewhere [15].
Virulence gene analysis by PCR-based assays
PCR-based assays were performed as described elsewhere
[16] for the following genes: four haemolysin genes (hla,
hld, hlg, and hlg-v), two leukocidin genes (lukM and lukE),
18 staphylococcal enterotoxin (se) genes (sea–see and seg–
ser), toxin shock syndrome toxin 1 (tst), three exfoliative
toxin (et) genes (eta, etb and etd), and 11 adhesin genes
(icaA, icaD, cna, eno, fnbA, fnbB, ebpS, clfA, clfB, ﬁb, and
bbp).
Susceptibility testing
Susceptibility testing of bacterial strains was performed
using the agar dilution method according to the CLSI
recommendations [17]. The tested antimicrobials included
penicillin G, oxacillin, ampicillin, cefazolin, ceftazidime,
cefotaxime, cefaclor, imipenem, meropenem, gentamicin,
kanamycin, rifampicin, ciproﬂoxacin, levoﬂoxacin, norﬂoxa-
cin, trimethoprim, sulphamethoxazole, clindamycin, erythro-
mycin, clarithromycin, azithromycin, linezolid, vancomycin,
teicoplanin, chloramphenicol, doxycycline, minocycline, and
tetracycline. The results of the susceptibility testing for
streptomycin, fusidic acid and fosfomycin were interpreted
in accordance with the recommendations of the Antibiotic
Committee of the French Microbiological Society [18]. The
susceptibility testing results for mupirocin were interpreted
according to the manufacturer’s recommendations [19].
The antimicrobial agents were gifts from their manufactur-
ers. Inducible resistance to clindamycin was detected using
the D-test with erythromycin (15 lg) and azithromycin
(15 lg) disks [20].
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Drug resistance gene analysis
Genes conferring resistance to b-lactams (mecA), tetracycline
(tetK and tetM), aminoglycosides (aac6¢/aph2) and macrolides
and lincosamide (ermA, ermB, ermC, and msrA/B) were
detected using PCR assays [20–22]. For ﬂuoroquinolone
resistance, mutations in gyrA (for DNA gyrase) and grlA
(for topoisomerase IV) were detected with the primer
set gyrA-F (5¢-CAGTGAAATGCGTGAATC-3¢) and gyrA-R
(5¢-CAATATCTTCCATTAACTCAGC-3¢), and the primer
set grlA-F (5¢-GTGCATTGCCAGATGTTC-3¢) and grlA-R
(5¢-TACCTTGAATAATACCACCAG-3¢), respectively. These
primer sets were designed on the basis on the gene
sequences of MSSA strain 476 (GenBank accession number
NC_002593). Screening for mutations in rpoB, which confer
resistance to rifampicin, was performed as previously
described [23].
Statistical analysis
Relationships between categorical variables were analyzed by
the chi-square test or Fisher’s exact test if 20% of the
expected values were <5. A p-value of <0.05 was considered
to be statistically signiﬁcant.
Results
Characterization of S. aureus isolates
Six coagulase types were detected among the 63 S. aureus
isolates: types IV, V, VII, VI, II, and III, representing 30 (48%),
16 (25%), seven (11%), ﬁve (8%), three (5%) and two (3%)
isolates, respectively (Fig. 1). Fourteen different PFGE types
(PFTs) were distinguished within the 63 S. aureus isolates
(Fig. 1). The 30 MRSA isolates fell into four PFTs (B, D, E,
and F). In contrast, the 33 MSSA isolates showed greater
diversity than the MRSA isolates. Ten different PFTs (A, C,
G, H, I, J, K, L, M, and N) were identiﬁed within the MSSA
group, and included three PFTs that were split into subtypes
(C, G, and I).
The agr typing allowed 42 (67%), 17 (27%) and four (6%)
of the 63 S. aureus isolates to be classiﬁed into agr groups 1,
4, and 3, respectively (Fig. 1). Nearly all of the MRSA isolates
(29/30) belonged to agr group 1. Two SCCmec types were
identiﬁed among the 30 mecA-positive isolates. Twenty-seven
(90%) of the S. aureus isolates were SCCmecIII and three
(10%) were SCCmecIVc (Table 2). Among the 63 isolates, 21
spa types were identiﬁed (Fig. 1). Twelve of the spa types
were already recorded in the spa database (http://tools.
egenomics.com/), and nine were novel types: 825, 826, 827,
828, 829, 830, 979, 980, and 981.
Finally, 11 ST types were identiﬁed, belonging to nine clo-
nal complexes. One MSSA isolate had a novel ST, ST1211
(Fig. 1).
Clonal characterization of MRSA isolates
On the basis of epidemiological characteristics, 28 HA-MRSA
and two CA-MRSA isolates were identiﬁed (Table 2). The
major MRSA clone was exclusively HA-MRSA and comprised
90% of the isolates (27/30). Although PFGE identiﬁed two
PFTs (D and E), both PFTs belonged to ST239, SCCmecIII.
PFTs D and E corresponded to spa type 3 (n = 16) and spa
type 351 (n = 11), respectively. Data on the virulence gene
proﬁle and antimicrobial resistance are shown in Table 2.
TABLE 1. Basic demographics of
patients and clinical origin and site
of acquisition of 63 Staphylococcus
aureus infections in Vladivostok,
Russia, August 2006 to April 2007
Characteristics
Total no. (%)
of patients/
infections, n = 63
Value for group (%)
p-Value
MRSA,
n = 30 (48)
MSSA,
n = 33 (52)
Patients
Gender
Female 21 (33) 8 (27) 13 (39) 0.2845
Male 42 (67) 22 (73) 20 (61)
Age
Mean years ± SD (range) 34.70 ± 20.03 (0–68) 41.00 ± 2057 (0–68) 28.97 ± 17.96 (0–68)
Age group (years)
0–34 30 (48) 10 (33) 20 (61) 0.0304a
35–68 33 (52) 20 (67) 13 (39)
Clinical origin of infections
Wound infection 33 (52) 21 (70) 12 (36) 0.0076a
Abscess (skin and soft tissue) 16 (26) 3 (10) 13 (39) 0.0094a
Pneumonia 9 (14) 3b (10) 6b (18) 0.4788
Bacteraemia 2 (3) 1b (3) 1b (3) 1
Joint infection 2 (3) 1 (3) 1 (3) 1
Peritonitis 1 (2) 1b (3) 0 0.4762
SD, standard deviation. Among three methicillin-resistant S. aureus (MRSA) pneumonia cases, only one had a fatal out-
come; among six methicillin-susceptible S. aureus (MSSA) pneumonia cases, four were of community origin and all
four had fatal outcomes.
aSigniﬁcant differences.
bCases with a fatal outcome.
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Strains belonging to spa type 351 were characteristically resis-
tant to rifampicin and were isolated from all of the hospitals
participating in this study. The molecular characterization and
drug resistance proﬁles of the minor MRSA clones are shown
in Table 2.
Clonal characterization of MSSA isolates
There were 33 MSSA isolates, separated into 17 (52%) HA-
MSSA and 16 (48%) CA-MSSA strains (Table 3). The major
MSSA clone comprised 48% of the isolates (16/33); they
were primarily community-acquired (12 CA-MSSA and four
HA-MSSA), and shared two PFTs (G and H). This clone was
ST121, with six related spa types (828, 466, 287, 830, 829,
and 827), which exhibited deletion and/or insertion of some
repeats or point mutations in one of the repeats (Fig. 2).
Notably, 57% (4/7) of isolates of the PFT H spa type 287
were community-acquired and caused pneumonia in patients,
who had a mean age of 17.75 years. All of these community-
acquired pneumonia cases were fatal. In spite of the
difference in spa types, all isolates of this ST121 MSSA
clone shared the same virulence gene pattern, and were
PVL-positive. The molecular characterization of the minor
MSSA clones is shown in Table 3.
In terms of drug resistance, 85% (28/33) of the MSSA
isolates were resistant to penicillin and ampicillin. The
MSSA isolates of hospital origin exhibited more antibiotic
resistance than those of community origin. On the basis
of the double-disk diffusion test results, all erythromycin-
resistant and clindamycin-susceptible isolates showed an
inducible macrolide–lincosamide–streptogramin B pheno-
type.
Drug resistance genes and sequence analysis
All phenotypically oxacillin-resistant isolates carried the mecA
gene, and all of the gentamicin/kanamycin-resistant isolates
possessed the aacA/aphD gene (Tables 2 and 3). The constit-
utive macrolide–lincosamide–streptogramin B phenotype and
the erm(A) gene predominated among the erythromycin-
resistant MRSA isolates (27/29), whereas the inducible
phenotype and the erm(C) gene were found in all of the
erythromycin-resistant MSSA isolates (7/7).
DNA sequencing of the rifampicin resistance-determining
region of the rifampicin-resistant isolates revealed an H481N
amino acid substitution.
Discussion
Reported here are the molecular characterization and anti-
microbial susceptibilities of S. aureus isolates obtained from
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FIG. 1. SmaI macrorestriction patterns of 63 Staphylococcus aureus isolates from four hospital laboratories in Vladivostok, Russia and their genetic
types. The pulsed-ﬁeld gel electrophoresis (PFGE) types (PFTs) were deﬁned by ‡80% similarity (UPMAG, Dice). Isolates with PFGE patterns with simi-
larity greater than 95%were considered to belong to the same PFT. PFGE patterns of one representative isolate from each PFT are shown. The number
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and 3. *The novel spa type. **The novel sequence type (ST). MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus.
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outpatients and inpatients at four hospital laboratories in
Vladivostok, Russia over an 8-month period in 2006–2007.
One major HA-MRSA ST239, SCCmecIII clone, resembling
the Brazilian/Hungarian clone, circulated in hospitals in
Russia. The Brazilian/Hungarian clone accounts for 70–80%
of the MRSA strains in the world, and its broad distribution
may be due to its advantageous properties with respect to
other clones, such as an enhanced ability to form bioﬁlm and
a tendency to acquire genes that confer resistance to
different classes of antimicrobial agents [24].
In this study, the Brazilian/Hungarian clone was multidrug-
resistant, which is in agreement with previous reports. More-
over, all of the HA-MRSA ST239-III, spa type 351 strains
isolated in this study were also resistant to rifampicin. All
rifampicin-resistant HA-MRSA ST239 isolates had the same
H481N substitution in the rifampicin resistance-determining
region. These observations suggest that it is the rifampicin-
resistant Brazilian/Hungarian MRSA clone that is spreading
through hospitals in Russia. Rifampicin is inexpensive, has a
broad spectrum of antimicrobial activity, and is used in clini-
cal practice in Russia when the aetiological agent of an infec-
tion is not yet conﬁrmed and/or when Mycobacterium
tuberculosis is suspected [25]. However, when rifampicin is
used as monotherapy, S. aureus quickly develops resistance
by selection for a point mutation that causes structural mod-
iﬁcations in the cellular target of the drug. Therefore, rifam-
picin should be retained for the treatment of life-threatening
S. aureus infections, e.g. necrotizing fasciitis, meningitis, or
infections of bone and orthopaedic implants, but should not
be used in monotherapy.
All HA-MRSA ST239 isolates belonging to the major
MRSA clone were resistant to sulphamethoxazole, in con-
trast to the other MRSA clones (ST8 and ST30) and all of
the MSSA clones isolated in this study. This result suggests
that sulphamethoxazole might serve as a phenotypic marker
with which to screen for the major HA-MRSA ST239 clone
in Russia.
Also isolated from both community-acquired and hospital-
acquired infections was the PVL-negative ST8 MRSA clone.
The molecular characteristics of this clone were similar to
those of the Lyon clone (ST8, SCCmecIV), which is present
throughout hospitals in France, where it replaced the previ-
ously dominant gentamicin-resistant Iberian clone (ST247,
SCCmecI) [26]. Although the prevalence of this clone is cur-
rently low in Russia, the tendency of this clone to replace other
clones warrants its continuous monitoring in the coming years.
PVL is considered to be a marker of CA-MRSA infections
in some countries. In this study, only one CA-MRSA isolate
was PVL-positive. In contrast to PVL-positive MRSA, an
exceptionally high prevalence (55%) of PVL-positive MSSAT
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isolates were found. These were represented by a dominant
ST121 clone with high diversity in their spa types. These
observations suggest that PVL-positive ST121 MSSA strains
have the potential for epidemic spread in Russia.
Furthermore, in this study, the ST121, spa type 287 MSSA
clone caused community-acquired pneumonia in young
patients, resulting in 100% mortality. This clone contains sev-
eral genes that mediate adhesion (e.g. cna and bbp) and toxin
genes (PVL and egc, which encodes at least ﬁve superantigens,
including staphylococcal enterotoxins G, I, M, N, and O).
Sequence analysis of ST121, spa type 287 MSSA isolates
revealed an R176H substitution in the PVL gene (the ‘H vari-
ant’ PVL) (data not shown). Recent reports suggested that
the ‘H variant’ of PVL was associated with high virulence and
mortality in a murine pneumonia model [27]. In contrast,
Bubeck Wardenburg et al. [28] failed to observe a signiﬁcant
difference in virulence in a mouse pneumonia model that
examined the ‘R variant’ PVL strains. Further studies are
needed to clarify the pathogenesis of S. aureus pneumonia,
but clinicians should take PVL production into account in the
therapeutic management of community-acquired S. aureus
pneumonia in Russia.
Some of the MSSA isolates had genetic backgrounds that
were identical to those found in pandemic MRSA clones.
Some examples of this include the following: ST45 MSSA
(PFT I), which shared the same ST as the MRSA Berlin clone;
ST1 MSSA (PFT J and PFT N), which had a genetic back-
ground identical to the Western Australian MRSA-1 clone;
ST5 MSSA (PFT L), which corresponded to the New York/
Japan clone; and clone ST30 MSSA (PFT A), which was a sin-
gle-locus variant of the MRSA Southwest Paciﬁc clone. These
observations strongly suggest that MSSA strains are impor-
tant both as causative agents of infections and as a potential
reservoir of epidemic MRSA clones.
In conclusion, the Brazilian/Hungarian MRSA clone, which
was resistant to nine groups of antimicrobials, including
rifampicin, was found to be dominant in the hospital settings
in Russia. Routine detection of this clone in clinical laborato-
ries can be easily performed by detection of its resistance to
sulphamethoxazole. Among the MSSA strains collected for
this study, there was a high prevalence of the PVL gene in
community isolates, which was a predictor of poor prognosis
in patients with CA-MSSA pneumonia. These clones should
be closely monitored, because of their apparently enhanced
virulence, which makes them a substantial public health
threat.
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